{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:46:35Z","timestamp":1775501195152,"version":"3.50.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Ki-67 is a key biomarker of tumor proliferation in breast cancer, yet its clinical correlates in this population, where disease is often detected at earlier stages, remain underexplored. This study aimed to identify factors independently associated with high Ki-67 expression among women investigated for suspected breast cancer at Unilabs Laboratory, Lusaka, Zambia. A retrospective cross-sectional analysis was conducted on 208 women suspected of having breast cancer through a laboratory-based screening program in Lusaka, Zambia (2019\u20132024). Demographic, clinical, and pathology data were extracted from laboratory records. Ki-67 expression, as the outcome variable, was dichotomized as low (&lt;20%) or high (&gt;20%). Variables significant in bivariate analysis (p\u2009&lt;\u20090.05) were included in a multivariable logistic regression model to identify correlates of high Ki-67 expression. The median age was 48 years (IQR: 40\u201363), and 46.2% (n\u2009=\u200996) exhibited high Ki-67 expression. In bivariate analysis, younger age, invasive ductal carcinoma, right breast involvement, progesterone receptor (PR) positivity threshold \u226510%, non-Quick Score scoring methods, and lack of fluorescence in situ hybridization (FISH) testing were associated with high Ki-67. However, in adjusted multivariable models, only older age (&gt;41 years, aOR: 0.43\u20130.46, p\u2009&lt;\u20090.05), PR positivity threshold \u226510% (aOR: 6.14\u20136.38, p\u2009&lt;\u20090.05), and use of non-Quick Score scoring methods (aOR: 10.5\u201314.9, p\u2009\u2264\u20090.002) remained significantly associated with high Ki-67, while other factors lost statistical significance after controlling for confounders. In this diagnostic cohort from Zambia, nearly half of women with breast cancer exhibited high Ki-67 expression, reinforcing its relevance even in early detection settings. The study identified younger age (\u226440 years), higher PR positivity threshold, and alternative scoring methods as independent correlates of high Ki-67, highlighting the importance of standardized biomarker assessment. Future studies should consider a prospective study design incorporating molecular subtyping to enhance the clinical interpretation of Ki-67 in similar populations.<\/jats:p>","DOI":"10.1371\/journal.pgph.0005752","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:39:18Z","timestamp":1775497158000},"page":"e0005752","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlates of Ki-67 proliferation index in a cohort of women with suspected breast cancer in Lusaka, Zambia"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9366-2027","authenticated-orcid":true,"given":"Joaquim","family":"Musamba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-0635","authenticated-orcid":true,"given":"David","family":"Chisompola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phinnoty","family":"Mwansa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley","family":"Kamvuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Situmbeko","family":"Liweleya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-5831","authenticated-orcid":true,"given":"Sepiso K.","family":"Masenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"1173","key":"pgph.0005752.ref001","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/bjr\/tqaf148","article-title":"Understanding global variation in breast cancer mortality","volume":"98","author":"MMA Elbasheer","year":"2025","journal-title":"Br J Radiol"},{"key":"pgph.0005752.ref002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"M Arnold","year":"2022","journal-title":"Breast"},{"issue":"1","key":"pgph.0005752.ref003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13690-024-01404-3","article-title":"Global, regional, and national trends in the burden of breast cancer among individuals aged 70 years and older from 1990 to 2021: an analysis based on the global burden of disease study 2021","volume":"82","author":"S Liu","year":"2024","journal-title":"Arch Public Health"},{"issue":"17","key":"pgph.0005752.ref004","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.3390\/cancers13174455","article-title":"Ki-67 as a prognostic biomarker in invasive breast cancer","volume":"13","author":"MG Davey","year":"2021","journal-title":"Cancers (Basel)"},{"key":"pgph.0005752.ref005","doi-asserted-by":"crossref","first-page":"1053125","DOI":"10.3389\/fonc.2023.1053125","article-title":"Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance","volume":"13","author":"X Hu","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"pgph.0005752.ref006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cellsig.2014.01.018","article-title":"AKT3 regulates ErbB2, ErbB3 and estrogen receptor \u03b1 expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice","volume":"26","author":"N Grabinski","year":"2014","journal-title":"Cell Signal"},{"key":"pgph.0005752.ref007","doi-asserted-by":"crossref","first-page":"154819","DOI":"10.1016\/j.prp.2023.154819","article-title":"Breast cancer molecular subtype and relationship with clinicopathological profiles among Vietnamese women: a retrospective study","volume":"250","author":"TM Thuc Nguyen","year":"2023","journal-title":"Pathol Res Pract"},{"issue":"6","key":"pgph.0005752.ref008","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5858\/134.6.907","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"134","author":"MEH Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"pgph.0005752.ref009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"AC Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"pgph.0005752.ref010","doi-asserted-by":"crossref","DOI":"10.1186\/s43168-024-00357-z","article-title":"The importance of Ki-67 proliferation index in small cell lung cancer","volume":"19","author":"SB Sa\u011fmen","year":"2025","journal-title":"Egypt J Bronchol"},{"issue":"11","key":"pgph.0005752.ref011","article-title":"Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer: an observational study in Asian patients","volume":"100","author":"EJ Jung","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pgph.0005752.ref012","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3892\/ol.2017.5609","article-title":"Current status of the prognostic molecular biomarkers in breast cancer: a systematic review","volume":"13","author":"G Kutomi","year":"2017","journal-title":"Oncol Lett"},{"issue":"6","key":"pgph.0005752.ref013","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/modpathol.2015.38","article-title":"An international study to increase concordance in Ki67 scoring","volume":"28","author":"M-YC Polley","year":"2015","journal-title":"Mod Pathol"},{"key":"pgph.0005752.ref014","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijc.IJC_610_18","article-title":"Study of ER, PR, HER2\/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes","volume":"57","author":"T Khande","year":"2020","journal-title":"Indian J Cancer"},{"key":"pgph.0005752.ref015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6890-13-5","article-title":"A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer","volume":"13","author":"T Kobayashi","year":"2013","journal-title":"BMC Clin Pathol"},{"issue":"2","key":"pgph.0005752.ref016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"R Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"pgph.0005752.ref017","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group","volume":"113","author":"TO Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"pgph.0005752.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325387","article-title":"Clinicopathological and molecular subtypes of breast cancer in the Eastern Cape, South Africa: a two-year retrospective study","volume":"20","author":"HG Kretzmann","year":"2025","journal-title":"PLoS One"},{"issue":"4","key":"pgph.0005752.ref019","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/PAI.0000000000001009","article-title":"A standardized investigational Ki-67 immunohistochemistry assay used to assess high-risk early breast cancer patients in the monarchE phase 3 clinical study identifies a population with greater risk of disease recurrence when treated with endocrine therapy alone","volume":"30","author":"MD Polewski","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"pgph.0005752.ref020","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD2-01","article-title":"Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE","volume":"81","author":"N Harbeck","year":"2021","journal-title":"Cancer Res"},{"key":"pgph.0005752.ref021","article-title":"Ki-67 and its relation with complete pathological response in patients with breast cancer","volume":"13","author":"S Wajid","year":"2021","journal-title":"Cureus"},{"issue":"8","key":"pgph.0005752.ref022","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/cancers17081333","article-title":"Oncologic outcomes of young breast cancer patients according to tumor biology","volume":"17","author":"M Henzler","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pgph.0005752.ref023","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1186\/s12885-025-14451-y","article-title":"Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive\/PR-positive and ER-positive\/PR-negative breast cancer","volume":"25","author":"Z Lu","year":"2025","journal-title":"BMC Cancer"},{"issue":"2","key":"pgph.0005752.ref024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10549-017-4270-0","article-title":"Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections","volume":"164","author":"AA Muftah","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"pgph.0005752.ref025","article-title":"Expression of Ki-67 in invasive breast carcinoma and its correlation with different clinicopathological features","volume":"16","author":"U Sandilya","journal-title":"Cureus"},{"issue":"1","key":"pgph.0005752.ref026","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12885-025-13724-w","article-title":"The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand","volume":"25","author":"P Wongmaneerung","year":"2025","journal-title":"BMC Cancer"},{"key":"pgph.0005752.ref027","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1038\/s41598-020-64523-1","article-title":"Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes","volume":"10","author":"Q Liang","year":"2020","journal-title":"Sci Rep"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0005752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:39:21Z","timestamp":1775497161000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0005752"}},"subtitle":[],"editor":[{"given":"Collins Otieno","family":"Asweto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0005752","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}